Panitumumab (Vectibix)

Recombinant human monoclonal antibody that binds to and inhibits the function of the EPIDERMAL GROWTH FACTOR RECEPTOR. It is used in the treatment of EGFR-expressing metastatic colorectal cancer that expresses wild-type ras gene (see GENES, RAS).

Also Known As:

Vectibix; ABX-EGF MAb; ABX-EGF Monoclonal Antibody; Panitumumab Antibody, Human; ABX EGF Monoclonal Antibody; Human Panitumumab Antibody; Monoclonal Antibody, ABX-EGF; Immunoglobulin, anti-(human epidermal growth factor receptor) (human monoclonal ABX-EGF heavy chain), disulfide with human monoclonal ABX-EGF light chain, dimer

Networked: 1101 relevant articles (183 outcomes, 347 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Siena, Salvatore: 37 articles (01/2020 - 05/2005)
2.	Peeters, Marc: 25 articles (10/2020 - 05/2007)
3.	Sartore-Bianchi, Andrea: 23 articles (11/2022 - 05/2005)
4.	Pietrantonio, Filippo: 21 articles (11/2022 - 12/2013)
5.	Bardelli, Alberto: 21 articles (01/2018 - 05/2005)
6.	Tabernero, Josep: 18 articles (01/2020 - 12/2008)
7.	Van Cutsem, Eric: 16 articles (01/2020 - 01/2007)
8.	Di Nicolantonio, Federica: 16 articles (12/2016 - 05/2005)
9.	Di Bartolomeo, Maria: 15 articles (11/2022 - 12/2013)
10.	Lonardi, Sara: 14 articles (11/2022 - 11/2015)

Related Diseases

1.	Colorectal Neoplasms (Colorectal Cancer) 09/01/2015 - "Panitumumab has proven efficacy in patients with metastatic or locally advanced colorectal cancer patients, provided that they have no activating KRAS mutation in their tumour. " 12/03/2007 - "In a randomised phase 3 trial, panitumumab significantly improved progression-free survival (PFS) in patients with refractory metastatic colorectal cancer (mCRC). " 05/01/2007 - "Panitumumab significantly improved PFS with manageable toxicity in patients with chemorefractory colorectal cancer." 06/01/2018 - "We conducted a phase I study to determine the recommended dose of FOLFOXIRI + panitumumab as first-line treatment for RAS wild-type metastatic colorectal cancer (mCRC). " 10/01/2012 - "Our findings suggested that panitumumab has great potential for effective treatment of patients with unresectable stageIV colorectal cancer."
2.	Neoplasms (Cancer) 11/10/2022 - "The radiolabeled %ID/g was significantly greater in tumors of 89Zr-panitumumab-treated mice that did not receive unlabeled panitumumab as a blocking control for AB-36, AB-37, and AB-53. " 01/01/2014 - "In patients with WT KRAS tumors, panitumumab-FOLFIRI significantly improved PFS versus FOLFIRI [median 6.7 versus 4.9 months; hazard ratio (HR) 0.82 [95% confidence interval (CI) 0.69, 0.97]; P = 0.023]. " 01/01/2012 - "The LS-174T tumor AUC of 204.13 ± 9.67 was significantly greater (P < 0.001) than the LS-174T tumor AUC of 36.45 ± 1.39 obtained from mice coinjected with 0.1 mg of panitumumab for blocking the target. " 01/01/2018 - "For patients with wild type RAS tumors, median overall survival (OS; hazard ratio [HR], 0.72; P = .015) and progression-free survival (PFS; HR, 0.45; P < .0001) were improved with panitumumab with BSC versus BSC. " 01/01/2009 - "This study evaluated safety, pharmacokinetics, and efficacy of 2 dose schedules and 2 infusion times of panitumumab in patients with advanced solid malignancies. "
3.	Sarcoma (Soft Tissue Sarcoma) 01/01/2015 - "Panitumumab and cetuximab have improved tumour response rate, progression-free survival, and OS in mCRC patients in whom the RAS (Rat Sarcoma) gene is of Wild Type (WT) status. " 01/01/2018 - "During the same period, seven patients with mCRC with Kirsten rat sarcoma viral oncogene homolog (KRAS) wild-type primary lesions who were administered irinotecan with panitumumab comprised the control group. " 10/01/2012 - "In the Greek NHS and Social Security Sickness Fund setting, panitumumab monotherapy potentially constitutes a cost-saving option (versus cetuximab monotherapy) in the management of patients with mCRC and no mutation of Kirsten rat sarcoma viral oncogene homolog." 06/01/2013 - "The randomized first-line trials, including the CRYSTAL trial, the OPUS trial, and the PRIME trial, have demonstrated the significant efficacy of cetuximab or panitumumab in patients with v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) wild-type tumors. " 01/01/2020 - "Neither cetuximab nor panitumumab induced Fcγ-CR T antitumor activity against Kirsten rat sarcoma (KRAS)-mutated HCT116, nonsmall-cell-lung-cancer, A549 and TNBC, MDA-MB-231 cells. "
4.	Neoplasm Metastasis (Metastasis) 10/01/2012 - "As the third-line treatment, panitumumab was applied for 2 courses, and a significant reduction in the size of liver metastases was observed. " 02/01/2018 - "In multiple regression analyses, panitumumab treatment, liver-only metastases and WT BRAF status were consistently associated with improved ETS and DpR outcomes. " 12/01/2013 - "Based on these results, we are now performing phase II non-randomized open labeled trial of chronomodulated HAI with systemic administration of panitumumab for patients with such advanced liver metastases (ccFLAP trial). " 01/01/2012 - "However, few data exist regarding HER1 status in the corresponding distant metastases, and little corresponding information is available regarding the localization of panitumumab at primary and metastatic lesions. " 03/01/2023 - "Because of liver metastasis progression, hepatectomy was performed after 6 courses of FOLFIRI plus panitumumab. "
5.	Squamous Cell Carcinoma of Head and Neck 01/01/2016 - "PRISM: Phase 2 trial with panitumumab monotherapy as second-line treatment in patients with recurrent or metastatic squamous cell carcinoma of the head and neck." 07/01/2009 - "To understand the in vivo kinetics of antibody delivery and localization, we performed small-animal PET studies with (64)Cu-labeled panitumumab in xenografts derived from 3 cell lines of human head and neck squamous cell carcinoma (HNSCC). " 08/01/2021 - "Combining Panitumumab With Anti-PD-1 Antibody in Cutaneous Squamous Cell Carcinoma of the Head and Neck After Inadequate Response to Anti-PD-1 Antibody Alone." 01/01/2021 - "Panitumumab as an effective maintenance treatment in metastatic squamous cell carcinoma of the head and neck." 01/01/2018 - "Another anti-EGFR-mAb (panitumumab) was used as the treatment agent in RM-HNSCC patients in the phase II PANI01trial. "

Related Drugs and Biologics

1.	Cetuximab (Erbitux)
2.	Bevacizumab (Avastin)
3.	Monoclonal Antibodies
4.	Oxaliplatin (Eloxatin)
5.	ErbB Receptors (EGF Receptor)
6.	Fluorouracil (Carac)
7.	Irinotecan (Camptosar)
8.	Leucovorin (Folinic Acid)
9.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
10.	Cisplatin (Platino)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Therapeutics
3.	Neoadjuvant Therapy
4.	Combination Drug Therapy (Combination Chemotherapy)
5.	Radiotherapy